Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer
Opdivo combined with paclitaxel showed anti-tumor activity in a phase 1/2 study of gastric cancer patients with a variety of tumor markers,... Read More
Investigational Anti-PD-1 Agent Shows Potential for Treatment of Unresectable or Metastatic MSI-H/dMMR Solid Tumors
The novel checkpoint inhibitor HLX10 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite instability-high or... Read More
Chatter Between Cell Populations Drives Progression of Gastrointestinal Tumors
Researchers at UCSD discovered that cancer-associated fibroblasts within gastrointestinal stromal tumors (GISTs) communicate with GIST cells to drive tumor growth.
Dynamic, personalized treatment approach may improve outcomes in gastroesophageal cancers
A University of Chicago study found that when treatments are customized for gastric cancer patients based on the genetic characteristics of their... Read More
Bemarituzumab Improves Gastric Cancer Survival Response Rates
In a study presented at ASCO GI, adding Five Prime’s experimental targeted drug to a modified FOLFOX chemotherapy regimen significantly improved survival... Read More
Epstein-Barr virus rewires host epigenomes to drive stomach cancer
Epstein-Barr virus is known to raise the risk of gastric cancer. A recent study explains how the virus “rewires” the epigenome to... Read More
Fluctuating expression of miR-584 in primary and high-grade gastric cancer
A recent study found that H. Pylori infection raises levels of a particular miRNA, which could be used as a biomarker for... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
Tumor-associated macrophages represent an exciting new target in the development of treatments for gastric cancer.
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
The FDA approved Deciphera Pharmaceuticals’ Quinlock (ripretinib) for the treatment of advanced gastrointestinal stromal tumors.
